NEURO61

Session information

Print

Neuroscience Frontier Symposium

[NFS-02] Neuroscience Frontier Symposium 02
Original discovery and therapy for SCA from Japan to the world

Wed. Sep 2, 2020 9:00 AM - 10:30 AM Room 10 (Okayama Prefectural Medical Association 2F miki anniversary Hall)

Chair：YoshitakaNagai（Department of Neurotherapeutics, Osaka University Graduate School of Medicine）,KinyaIshikawa（The Center for Personalized Medicine for Healthy Aging, Tokyo Medical and Dental University）

[NFS-02-1] Pathogenesis of spinocerebellar ataxia type 31 (SCA31)

○Kinya Ishikawa1, Miwa Higashi2, Michi Okita1, Hanako Aoki2, Meiko Asaka3, Taro Ishiguro2, Nozomu Sato2, Yoshitaka Nagai4, Dai Yanagihara3, Takanori Yokota2 (1.The Center for Personalized Medicine for Healthy Aging, Tokyo Medical and Dental University, Japan, 2.Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, Japan, 3.Graduate School of Arts and Sciences, the University of Tokyo, Japan, 4.Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Japan)

Spinocerebellar ataxia (SCA) is neurodegenerative diseases affecting mainly cerebellum and brainstem, and new subtypes and pathologies of SCAs have been continuously discovered in the world. Especially, SCA31 and SCA36 (nicknamed Asidan) were first found in Japanese, and their clinical and pathological features are quite unique compared with other SCAs. Recent discovery of repeat associated non-ATG (RAN) translation in the pathogenesis of hereditary SCAs carrying repeat expansion mutations has tremendously extended our understanding in the pathogenesis of SCA and other neurodegenerative diseases. Furthermore, the development of new therapy for SCAs have been extensively investigated in Japan and the world. The aim of this symposium is to learn and discuss the current clinical, pathological and therapeutic findings of SCAs for Japanese and Asian neurologists and neuroscientists.

[NFS-02-2] Current clinical characteristics of Asidan (SCA36)

○Yasuyuki Ohta (Department of Neurology, Okayama University, Japan)

Spinocerebellar ataxia (SCA) is neurodegenerative diseases affecting mainly cerebellum and brainstem, and new subtypes and pathologies of SCAs have been continuously discovered in the world. Especially, SCA31 and SCA36 (nicknamed Asidan) were first found in Japanese, and their clinical and pathological features are quite unique compared with other SCAs. Recent discovery of repeat associated non-ATG (RAN) translation in the pathogenesis of hereditary SCAs carrying repeat expansion mutations has tremendously extended our understanding in the pathogenesis of SCA and other neurodegenerative diseases. Furthermore, the development of new therapy for SCAs have been extensively investigated in Japan and the world. The aim of this symposium is to learn and discuss the current clinical, pathological and therapeutic findings of SCAs for Japanese and Asian neurologists and neuroscientists.

[NFS-02-3] Development of disease-modifying therapy for polyglutamine-linked SCA

○Yoshitaka Nagai (Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Japan)

Spinocerebellar ataxia (SCA) is neurodegenerative diseases affecting mainly cerebellum and brainstem, and new subtypes and pathologies of SCAs have been continuously discovered in the world. Especially, SCA31 and SCA36 (nicknamed Asidan) were first found in Japanese, and their clinical and pathological features are quite unique compared with other SCAs. Recent discovery of repeat associated non-ATG (RAN) translation in the pathogenesis of hereditary SCAs carrying repeat expansion mutations has tremendously extended our understanding in the pathogenesis of SCA and other neurodegenerative diseases. Furthermore, the development of new therapy for SCAs have been extensively investigated in Japan and the world. The aim of this symposium is to learn and discuss the current clinical, pathological and therapeutic findings of SCAs for Japanese and Asian neurologists and neuroscientists.

[NFS-02-4] Antisense oligonucleotide therapy in spinocerebellar ataxia type 3 (SCA3)/Machado-Joseph disease

○Henry L. Paulson (University of Michigan, USA)

Spinocerebellar ataxia (SCA) is neurodegenerative diseases affecting mainly cerebellum and brainstem, and new subtypes and pathologies of SCAs have been continuously discovered in the world. Especially, SCA31 and SCA36 (nicknamed Asidan) were first found in Japanese, and their clinical and pathological features are quite unique compared with other SCAs. Recent discovery of repeat associated non-ATG (RAN) translation in the pathogenesis of hereditary SCAs carrying repeat expansion mutations has tremendously extended our understanding in the pathogenesis of SCA and other neurodegenerative diseases. Furthermore, the development of new therapy for SCAs have been extensively investigated in Japan and the world. The aim of this symposium is to learn and discuss the current clinical, pathological and therapeutic findings of SCAs for Japanese and Asian neurologists and neuroscientists.